Spotlight on Eltrombopag in the Treatment of Children with Chronic Immune Thrombocytopenia

Overview

Journal Pediatric Health Med Ther

Publisher Dove Medical Press

Date 2018 Feb 2

PMID 29388634

Citations 1

Authors

Michele P Lambert

Affiliations

Soon will be listed here.

Abstract

Pediatric data on the use of thrombopoietin receptor agonists are fairly limited. The recent approval of eltrombopag by the US Food and Drug Administration for children aged ≥1 year, based on data from two randomized, placebo-controlled clinical trials, may lead to the increased use of this drug in clinical practice, and therefore, it is important to have a basic understanding of the biology, pharmacokinetics, safety, and efficacy of the medication.

Citing Articles

Spotlight on eltrombopag in pediatric ITP in China: a long-term observational study in real-world practice.

Cheng X, Fu L, Ma J, Gu H, Chen Z, Zhao L Blood Adv. 2021; 5(19):3799-3806.

PMID: 34605871 PMC: 8679667. DOI: 10.1182/bloodadvances.2020004110.

References

Williams D, Peng B, Bailey C, Wire M, Deng Y, Park J . Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. Clin Ther. 2009; 31(4):764-76. DOI: 10.1016/j.clinthera.2009.04.010. View

Terrell D, Beebe L, Vesely S, Neas B, Segal J, George J . The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports. Am J Hematol. 2010; 85(3):174-80. DOI: 10.1002/ajh.21616. View

Makar R, Zhukov O, Sahud M, Kuter D . Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists. Am J Hematol. 2013; 88(12):1041-4. DOI: 10.1002/ajh.23562. View

Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M . Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001; 98(12):3241-8. DOI: 10.1182/blood.v98.12.3241. View

Neunert C, Buchanan G, Imbach P, Bolton-Maggs P, Bennett C, Neufeld E . Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS). Blood. 2013; 121(22):4457-62. DOI: 10.1182/blood-2012-12-466375. View

Neunert C, Lim W, Crowther M, Cohen A, Solberg Jr L, Crowther M . The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011; 117(16):4190-207. DOI: 10.1182/blood-2010-08-302984. View

Mori M, Kato M, Koh K, Hanada R . Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP. Rinsho Ketsueki. 2015; 56(5):511-3. DOI: 10.11406/rinketsu.56.511. View

Neunert C, Despotovic J, Haley K, Lambert M, Nottage K, Shimano K . Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study. Pediatr Blood Cancer. 2016; 63(8):1407-13. PMC: 5718620. DOI: 10.1002/pbc.26003. View

Elalfy M, Abdelmaksoud A, Eltonbary K . Romiplostim in children with chronic refractory ITP: randomized placebo controlled study. Ann Hematol. 2011; 90(11):1341-4. DOI: 10.1007/s00277-011-1172-9. View

10.

Bussel J, Garcia de Miguel P, Despotovic J, Grainger J, Sevilla J, Blanchette V . Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol. 2015; 2(8):e315-25. DOI: 10.1016/S2352-3026(15)00114-3. View

11.

Kuter D . The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013; 98(1):10-23. DOI: 10.1007/s12185-013-1382-0. View

12.

Wire M, Bruce J, Gauvin J, Pendry C, McGuire S, Qian Y . A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when.... Clin Ther. 2012; 34(3):699-709. DOI: 10.1016/j.clinthera.2012.01.011. View

13.

Ballem P, Segal G, Stratton J, Gernsheimer T, Adamson J, Slichter S . Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest. 1987; 80(1):33-40. PMC: 442198. DOI: 10.1172/JCI113060. View

14.

Wang X, Li A . Successful use of eltrombopag in a child with refractory immune thrombocytopenia: case study and literature review. Blood Coagul Fibrinolysis. 2015; 27(7):825-827. DOI: 10.1097/MBC.0000000000000474. View

15.

McMillan R, Luiken G, Levy R, Yelenosky R, Longmire R . Antibody against megakaryocytes in idiopathic thrombocytopenic purpura. JAMA. 1978; 239(23):2460-2. DOI: 10.1001/jama.239.23.2460. View

16.

Cines D, Cuker A, Semple J . Pathogenesis of immune thrombocytopenia. Presse Med. 2014; 43(4 Pt 2):e49-59. DOI: 10.1016/j.lpm.2014.01.010. View

17.

Ramaswamy K, Hsieh L, Leven E, Thompson M, Nugent D, Bussel J . Thrombopoietic agents for the treatment of persistent and chronic immune thrombocytopenia in children. J Pediatr. 2014; 165(3):600-5.e4. DOI: 10.1016/j.jpeds.2014.03.060. View

18.

Bussel J, Buchanan G, Nugent D, Gnarra D, Bomgaars L, Blanchette V . A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood. 2011; 118(1):28-36. DOI: 10.1182/blood-2010-10-313908. View

19.

Kaushansky K, Lok S, Holly R, Broudy V, Lin N, BAILEY M . Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature. 1994; 369(6481):568-71. DOI: 10.1038/369568a0. View

20.

Wendling F, Maraskovsky E, Debili N, Florindo C, Teepe M, Titeux M . cMpl ligand is a humoral regulator of megakaryocytopoiesis. Nature. 1994; 369(6481):571-4. DOI: 10.1038/369571a0. View